Maximilian Werner
A5076528060- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Myasthenia Gravis and Thymoma
- Tumors and Oncological Cases
- Medical Imaging and Pathology Studies
- Genetic factors in colorectal cancer
- Oral and Maxillofacial Pathology
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
University Hospital Carl Gustav Carus
2025
Helmholtz-Zentrum Dresden-Rossendorf
2025
Technische Universität Dresden
2025
National Center for Tumor Diseases
2020-2025
Deutschen Konsortium für Translationale Krebsforschung
2025
German Cancer Research Center
2022
Heidelberg University
2022
Abstract The benefit of molecularly-informed therapies in cancer unknown primary (CUP) is unclear. Here, we use comprehensive molecular characterization by whole genome/exome, transcriptome and methylome analysis 70 CUP patients to reveal substantial mutational heterogeneity with TP53 , MUC16 KRAS LRP1B CSMD3 being the most frequently mutated known cancer-related genes. common fusion partner FGFR2 focal homozygous deletion affects CDKN2A . 56/70 (80%) receive genomics-based treatment...
Abstract Precision oncology offers new cancer treatment options, yet sequencing methods vary in type and scope. In this study, we compared whole-exome/whole-genome (WES/WGS) transcriptome (TS) with broad panel by resequencing the same tumor DNA RNA as well normal tissue for germline assessment, from 20 patients rare or advanced tumors, who were originally sequenced WES/WGS ± TS within DKFZ/NCT/DKTK MASTER program 2015 to 2020. Molecular analyses resulted a median number of 2.5 (gene panel)...
Thymic epithelial tumors (TETs) are rare malignancies with limited treatment options and underexplored molecular features. We examined the genomic landscape therapeutic outcomes in 81 patients advanced TETs, including thymic carcinomas (TCs), thymomas, neuroendocrine neoplasms (TNENs), who were enrolled MASTER trial, a prospective observational precision oncology trial. Using whole-genome-sequencing whole-exome-sequencing analysis, transcriptome methylome we identified distinct features...
Abstract Targeted panel sequencing of known genetic driver alterations is an established part the initial clinical diagnostic routine for many tumors. However, exploratory advanced and rare cancers remains experimental. MASTERsg a prospective broad program that utilizes TSO500 TST170 DNA/RNA assays to identify therapeutically relevant in patients with cancers. The pipeline detects copy number variations (CNVs) by dividing CNV caller’s raw data into gene-specific bins, each consisting 50-250...
Abstract Molecularly-guided therapy can improve treatment outcomes in CUP, a heterogeneous group of cancers with very limited prognosis. Within DKFZ/NCT/DKTK MASTER, clinically embedded prospective precision oncology registry trial, patients receive molecularly-guided recommendations (TR) based on whole genome/exome sequencing (WGS/WES), transcriptome and methylome analysis from dedicated molecular tumor board (MTB). We retrospectively added phosphoproteomic (PPA) to assess its potential...
Abstract Cancers of unknown primary site (CUPs) represent a heterogeneous group metastatic tumors, which accounts for 3-5% malignancies. Due to the poor prognosis and limited local systemic treatment options, there is an urgent need improvement molecularly driven strategies. We investigated molecular profile clinical course 70 patients enrolled in prospective precision oncology registry trial conducted by National Center Tumor Diseases (NCT) Heidelberg/Dresden German Cancer Consortium (DKTK)...